TrialSignal
Clinical trial intelligence report
Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00400673-Jul 28, 2026
NCT ID
NCT00400673
Status
COMPLETED
Phase
PHASE2
Sponsor
Northern Italy Leukemia Group
Executive brief
Investment-Ready Snapshot
Two-Step Remission Induction With Risk-Oriented Consolidation (High-Risk: Allogeneic Stem Cell Transplant; Standard-Risk: Multicycle High-Dose Cytarabine With Autologous Blood Stem Cell Support) for Adult Acute Myelogenous Leukemia is a PHASE2 clinical asset sponsored by Northern Italy Leukemia Group in Acute Myelogenous Leukemia. SEO and diligence focus: Two-step remission induction and risk-oriented consolidation, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00400673
Indication
Acute Myelogenous Leukemia
Modality
behavioral intervention
Target
Two-step remission induction and risk-oriented consolidation
Intervention
Two-step remission induction and risk-oriented consolidation
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.